Production & Manufacturing

The pharmaceutical industry is experiencing a fundamental shift away from the traditional “blockbuster drug” model toward increasingly sophisticated precision medicine manufacturing strategies that prioritize individual patient needs over mass-market volume. This transformation represents far more than a simple adjustment...

Pharmaceutical supply chains are fundamentally evolving as global disruptions, regulatory demands, and patient expectations converge to redefine how drugs reach the market. In today’s environment, pharmaceutical supply chain resilience depends not only on physical infrastructure and traditional logistics but...

Governor Jenniffer A. González Colón, along with Sebastián Negrón Reichard, the Economic Development and Commerce Secretary, has announced that Eli Lilly and Company, also known as Lilly, is going to invest over $1.2bn to modernize Puerto Rico operations. This...

Pharmaceutical businesses increasingly outsource their product development and manufacture to Contract Development and manufacture Organizations (CDMOs), which operate in a fragmented sector that is experiencing significant restructuring. However, a lot of CDMOs put their competitiveness at risk by not...

It is well to be noted that in 2025, a minimum of 14 major pharmaceutical companies across the world went ahead and announced plans to broaden their manufacturing presence in the U.S. so as to lessen the supply chain...

As the U.S. production investments continue to roll in 2025, LTS Lohmann, the German pharmaceutical technology specialist, is joining the table with a deal to boost its CDMO firepower in the U.S. Like many other contract manufacturing expansions that have...

AstraZeneca has gone on to announce a newly expanded manufacturing facility located in Coppell, Texas, U.S., which is going to double production of Lokelma for the advantages of patients across the U.S. as well as around the world. This $445 million...